Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Celgene and Oxford University are together embarking on a fellowship programme to support training in translational research and facilitate skills transfer between academia and industry. Funding will be awarded to Oxford Principal Investigators to support projects that can demonstrate a clear translational value to the advancement of therapeutics.


The programme will create a research and training interface with the goal of scientific translation and especially target validation through sharing of expertise and resources.

Funding will be awarded to Oxford Principal Investigators for projects that can demonstrate a clear translational value to the advancement of therapeutics in high interest areas for the company. The funding may be used to support two distinct groups of trainees:

  • Physician investigators interested in obtaining real life experience with drug development in an industrial setting 
  • Laboratory and informatics based research scientists (postdocs) committed to translational science

This programme offers outstanding candidates the opportunity to gain exposure to the field of commercial drug discovery and development with an assigned company mentor and the prospect, where appropriate, of spending some time based in Celgene's laboratories. The fellowships are designed to support basic researchers (Grade 7/8) or clinical researchers (Grade E64) at full economic cost for 2-3 years and have ample running costs.  It is envisaged that the trainee will spend an appropriate amount of time in Celgene labs to learn ‘how the other half lives and works’.


Projects should foster the innovative application of emerging concepts from both Oxford and Celgene to advance translational science designed to accelerate effective development and registration of novel therapies. Projects should demonstrate:

  • Clear translational value to advancement of therapeutics in defined high interest areas 
  • Innovative application of emerging technologies for advancement of translational problems
  • Advancement of informatics-based applications to emerging therapeutics or redefinition of disease cohorts

To learn about projects funded by the Oxford-Celgene programme see here.


  • Modulation of the immune system for treatment of oncologic or inflammatory diseases 
  • Novel targets in protein homeostasis pathways 
  • Novel targets in epigenetic pathways
  • Methods for evaluating molecular and cellular consequences of modulating epigenetic targets 
  • Targets and biomarkers for fibrosing, hematologic, rheumatic, dermatologic and neuroinflammatory disorders 
  • Methods for immuno-phenotyping of human subjects in oncology and immune-mediated disease


Status: Closed

Previous application form

Information for Departmental Administrators.


Steering committee